-
-
-
-
-
-
-
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
-
-
-
-
-
-
-
Eisai completes FDA submission for LEQEMBI subcutaneous starting dose
-
-
-
-
-
-
-
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
-
-
-
-
-
-
-
Biogen (BIIB) PT Lowered to $241 at H.C. Wainwright
-
-
-
-
-
-
-
Biogen (BIIB) PT Lowered to $251 at Mizuho
-
-
-
-
-
-
-
Biogen (BIIB) PT Raised to $360 at Piper Sandler into Zuranolone PDUFA
-
-
-
-
-
-
-
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
-
15,546 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

